The findings suggest that reconsideration of current clinical guidelines, which support MRI only for symptomatic brain ...

Several studies show that isolation is very common among those diagnosed with metastatic breast cancer. However, there are ...

If you have metastatic breast cancer, you may need help from loved ones and your medical team along the way. Here’s how to ...

After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with ...

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

Katrina Cooke and Ashley Dostefano share their personal journeys, reflecting on the challenges they faced, the victories they ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.